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Abstract 
Introduction: The reliability of clinician grading of systemic sclerosis (SSc)-related 
digital ulcers (DUs) has been reported to be poor to moderate at best, which has 
important implications for clinical trial design. The aim of this study was to examine the 
reliability of new proposed UK Scleroderma Study Group DU definitions amongst UK 
clinicians with an interest in SSc. 
 
Methods: Raters graded (through a custom-built interface) 90 images (80 unique and 
10 repeat) of a range of digital lesions collected from patients with SSc. Lesions were 
graded on an ordinal scale of severity: ‘no ulcer’, ‘healed ulcer’, or ‘DU’.  
 
Results: Twenty-three clinicians: 18 rheumatologists, 3 dermatologists, one hand 
surgeon and one specialist rheumatology nurse, completed the study. A total of 2070 
(1840 unique + 230 repeat) image gradings were obtained. For intra-rater reliability, 
across all images the overall weighted kappa coefficient was high (0.71) and was 
moderate (0.55) when averaged across individual raters. Overall inter-rater reliability 
was poor (0.15).  
 
Conclusion: Although our proposed DU definitions had high intra-rater reliability, the 
overall inter-rater reliability was poor. Our study highlights the challenges of DU 
assessment by clinicians with an interest in SSc, and provides a number of useful 
insights for future clinical trial design. Further research is warranted to improve the 
reliability of DU definition/rating as an outcome measure in clinical trials, including 
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examining the role for objective measurement techniques, and the development of DU 
patient reported outcome measures. 
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Introduction 
The reliability of rheumatologists grading digital ulcers (DUs) in patients with systemic 
sclerosis (SSc) has been reported to be poor to moderate at best (1–3), which is a 
major concern in the design of future clinical trials. Despite a number of drug therapies 
(4–7) to prevent and treat incident DUs, recurrent DUs remain a major source of pain 
and disability in some patients with SSc(8). There is a strong unmet clinical need to 
broaden therapeutic options to reduce the burden of SSc-DU disease, underpinning 
the need for high quality clinical trials. 
 
Recent multi-centre clinical trials of drug therapies for DUs have used different 
definitions for DUs in their study design. In general, previous definitions (5,7,9,10) 
have included a loss of surface epithelisation and with a discernible depth. Many 
studies have only included those DUs which occur on the fingertips, as these are 
considered ‘ischaemic’ and therefore presumably most likely to respond to vascular 
therapies, excluding those which occur over the extensor aspect of the fingers. There 
are also a number of digital lesions (e.g. pitting scars and fissures) which are common 
in patients with SSc, that can be very challenging to distinguish from DUs. 
Furthermore, the inclusion of DUs in the current ACR/EULAR SSc classification 
criteria (11) highlights the importance of accurate definition of DUs in patients with 
SSc. 
 
Against this background, a United Kingdom Scleroderma Study Group (UKSSG) 
working group was convened to develop and test new DU definitions. The aim of this 
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study was to examine the reliability of the proposed DU definitions amongst UK 
clinicians with an interest in SSc. 
 
Methods 
UKSSG working group 
Under the auspices of the UKSSG, a working group was assembled comprising 8 UK-
based rheumatologists with an interest in SSc, an international SSc expert, a 
dermatologist, a hand surgeon and a rheumatology specialist nurse. A statistician with 
extensive experience of reliability research and two patients with SSc with a history of 
DUs were also members of the working group.  
 
Consensus meeting and derivation of proposed DU definitions 
A DU consensus meeting was convened at the University of Manchester on the 24th 
November 2015. Previous DU definitions and issues around the challenges of DU 
grading were discussed. A key issue that emerged from the meeting was that different 
outcome measures might be required for preventive studies versus those studies 
investigating treatments for DUs. After the meeting, based upon the discussions, 
proposed DU definitions were drafted. These were then sent to the members of the 
working group for comment before being finalised. The final definitions for ‘no ulcer’, 
‘healed ulcer’ and ‘DU’ are presented in Table 1. 
 
Study design and participants  
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Eighty clinical images of a range of digital lesions (mainly DUs) from our previous 
reliability study (3) were used to conduct the grading exercise. These were 
prospectively selected by two individuals (MH and AH) to encompass the range of 
digital lesions observed in patients with SSc-spectrum disorders. A gangrenous digit 
was specifically included, as this is a controversial issue in the definition of DUs. As 
previously described (3) a clinical photograph of the digital lesion was obtained by a 
trained medical photographer; with a 1 cm graded scale positioned in close proximity 
to the lesion, to give raters an indication of the lesion size. Patient and lesion 
characteristics have been previously reported (3). The study was approved by the 
National Research Ethics Committee East of England-Hatfield, and all patients 
provided signed informed consent. 
 
A new custom-built, secure web-based interface was constructed to both display and 
record the grading of the clinical images. All clinical members of the UKSSG (and 
members of the working group) were invited to participate in the web-based study. On 
the ‘entry’ screen the proposed DU definitions were presented without any exemplar 
images. The definitions could be recalled for review throughout each rater’s 
participation in the study. Each rater graded 90 images: 80 unique and then 10 
repeated images ('randomly selected from the first 50) to allow an assessment of intra-
rater reliability. The unique images were displayed in a randomised order to each rater. 
Raters graded each image according to the proposed definitions on a 3-point ordinal 
scale of severity: either ‘no ulcer’ (0), ‘healed ulcer’ (1) or ‘DU’ (2). Raters had only 
one opportunity to score the image before choosing to move onto the next image. 
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Statistical analysis 
The reliability of categorical data (here 'no ulcer', 'healed ulcer' and 'DU') can be 
assessed by using kappa coefficients, which calculate the level of agreement between 
raters. Where the scale is ordered a weighted kappa coefficient (which is also an 
intraclass coefficient) is used. Similarly to our previous studies(1,3), intra-rater 
reliability was assessed using a weighted kappa coefficient with quadratic weights. 
This was calculated for each grader before taking the mean to obtain an overall figure. 
Inter-rater reliability assessment was based on the first observation of an image by a 
rater. One-way ANOVA was used estimate the to assess overall inter-rater reliability, 
which gives an estimate of the kappa coefficient (12). Data was dichotomised by 
adjoining adjacent categories which could be considered as applicable to (a) 
‘preventative studies’ (i.e. no ulcer vs healed ulcer and DU) and (b) ‘studies of 
treatments for DUs’ (i.e.  no ulcer and healed ulcer vs DU). It has been suggested that 
the kappa can be interpreted as no better than chance alone (<0), poor (0.01–0.20), 
fair (0.21–0.40), moderate (0.41–0.60), substantial (0.61–0.80), almost perfect (0.81–
0.99), and perfect (1) agreement between raters (13). All statistical analyses on the 
data were performed using STATA, version 13. 
 
Results 
23 UK clinicians (raters): 18 rheumatologists, three dermatologists, one orthopaedic 
hand surgeon and one specialist rheumatology nurse successfully completed the 
study. A total of 2070 (1840 unique + 230 repeat) image gradings were obtained.  
 
Intra-rater reliability  
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The overall intra-rater reliability was good. Across all images (n=230), irrespective of 
the individual rater the overall weighted kappa () coefficient was 0.71 (95% CI = 0.63 
– 0.79), and was moderate when averaged per individual raters ( = 0.55, SD = 0.31). 
Intra-rater reliability was high for both the dichotomised analyses of “no ulcer” vs. 
“healed ulcer and DU” ( = 0.70, 95% CI = 0.62 – 0.79) and “no ulcer and healed ulcer” 
vs. “DU” ( = 0.77, 95% CI = 0.67 – 0.86). 
 
Inter-rater reliability 
The overall inter-rater reliability was poor ( = 0.15, 95% CI = 0.10 – 0.21). Inter-rater 
reliability was fair for the dichotomised analyses of “no ulcer” vs. “healed ulcer and 
“DU” ( = 0.25, 95% CI = 0.19 – 0.31) and moderate for “no ulcer and healed ulcer” 
vs. “DU” ( = 0.41, 95% CI = 0.33 – 0.49). 
 
Figure 1 illustrates a number of example images with high or low agreement between 
raters.  
  
Discussion 
The key finding of our study is that although our proposed UKSSG DU definitions had 
good intra-rater reliability, the agreement between raters was poor. This further 
confirms the urgent need to develop more reliable methods for the assessment of DUs 
as outcome measures in multi-centre, multi-rater studies. 
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The overall inter-rater reliability was lower than previously reported (1–3). In our 
previous web-based DU reliability study (3), the addition of ‘real world’ (e.g. pain and 
discharge) clinical contextual information did not significantly increase the inter-rater 
reliability ( = 0.32 without or 0.36 without the contextual information). The poor 
agreement between raters may be related to the intrinsic properties/performance of 
our proposed definitions and/or to differences in rater opinion. The high intra-rater 
reliability further confirms the importance for the same individual to assess patients in 
clinical trials, to minimise the impact of differences in opinion between raters. 'The 
incorporation of centralised analysis of lesion images by a panel of trained experts 
might be one approach to ensuring uniformity in lesion assessment in clinical trials of 
SSc-DU. 
 
A key strength of our study is that the definitions were developed by a broad working 
group including colleagues from related specialities (dermatology, orthopaedic hand 
surgery and rheumatology specialist nursing), and with patient representation. 
Furthermore, a large image bank was used facilitating >2000 individual assessments, 
allowing comprehensive analysis of rater reliability. 
 
Our UKSSG definitions can be considered as complementary to the recently proposed 
definitions by the World Scleroderma Foundation (WSF) (14). Both (sets of) definitions 
feature a loss of depth/epithelium as a central feature of DUs. In addition, both 
recognise that DUs are often covered by an overlying crust or eschar, and therefore a 
caveat is added to both, that if debridement would likely confirm a DU, then the lesion 
should be classified as a DU. Neither set of definitions included an ‘unclassifiable’ 
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category, as this was not felt to be helpful in the grading of DUs. In our definitions, we 
chose to encompass the spectrum of DU disease, including extensor DUs and those 
which occur in relation to subcutaneous calcinosis. 
 
At present, assessment of treatment efficacy in clinical trials is primarily based upon 
clinician opinion alone: patient opinion has been less widely studied. In a recent 
reliability study, the agreement between individual patients and rheumatologists was 
poor with and without the clinical context (0.28 and 0.19, respectively) (3). Of 
relevance to our proposed UKSSG (and WSF) DU definitions, in our previous study 
we did not information graders with a history of lesion debridement (the role of which 
in the management of SSc-DUs is currently a controversial issue). The appearance of 
digital lesions does not always correlate with patient symptoms and there is a major 
unmet need to develop patient reported outcome (PRO) instruments for capturing the 
multifaceted patient experience of SSc-DU to facilitate future clinical trials. 
 
Our study has a number of important considerations. This was a web-based study and 
it could be argued that there is an important difference between assessing clinical 
photographs and physical examination of lesions. In our study, we chose not to provide 
exemplar images, because we wanted to assess the reliability of our proposed UKSSG 
definitions only, and such images could potentially have an additional impact on rater 
grading. The inter-rater reliability of clinicians physically assessing digital lesions using 
the WSF definition was reported to be 0.5 (14) but the authors accepted that both the 
number of patients assessed and the number of clinicians who graded the lesions in 
this exercise was small (both n=7). Similarly, the study by Baron et al (2), in which 
 12 
raters physically assessed DUs, included only a limited number (n=10) of raters.  It is 
unlikely that rater recall accounted for the high intra-rater reliability in the present study 
due to the large number of images assessed and the systematic approach taken to 
repeat image assessment.  
 
The limitations of clinician-grading highlight the potential value of more objective 
methods for measuring DUs in future clinical trials, e.g. ultrasound assessment of DU 
surface area and/or depth. In a pilot study in 10 patients with SSc with 15 DUs, high-
frequency ultrasound was found to be a feasible method to measure a range of SSc-
related DUs (15). Similarly, Sulliman et al (16) reported (currently only in abstract form) 
successful measurement of SSc-related DUs by musculoskeletal ultrasound. In a 
recent study (17), digital planimetry by free hand or fitting a semi-eclipse was found to 
be a reliable method to measure DU surface area, with good agreement between the 
two techniques. Baron et al (2) reported moderate intra- (0.57) and inter-rater (0.48) 
reliability for the measurement of DU by surface area, in a study using digital callipers.  
 
Our study highlights a number of important lessons for the design of future SSc clinical 
trials, relating to the definition of DUs. Firstly, the development of our proposed DU 
definitions benefited from a diverse multi-disciplinary working group, including patient 
representation. Secondly, different outcome measures may be needed in preventative 
studies compared to those of treatments for DUs. In our study, inter-rater reliability 
was found to be highest in the context of ‘studies of treatments for DUs’ compared to 
‘preventative studies' and overall reliability, which could indicate raters find this 
classification of lesions (i.e.  ulcer versus healed/no ulcer) useful in this context. 
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Thirdly, the role of training to improve the reliability of rater grading warrants 
investigation. Finally, a number of images had very high or perfect inter-rater 
agreement (Figure 1), and future studies should consider the production of an ‘atlas’ 
of exemplar images to inform DU definitions, both for training purposes and as an aide-
memoire’. 
 
In conclusion, although our proposed DU definitions had high intra-rater reliability, the 
agreement between raters was poor. Our study provides a number of invaluable 
insights for the design of future DU clinical trials. Future research is needed to improve 
the reliability of clinician assessment of SSc-DUs as an outcome measure and explore 
the complementary roles of objective measurement techniques and PRO instruments 
in assessing the severity and impact of SSc-DU.  
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Digital ulcer A lesion (on the finger on or distal to the metacarpophalangeal joint) 
with loss of surface epithelisation and a visually discernible depth. 
The ulcer bed is often wet in appearance with surface slough. 
 
The peri-lesional skin surrounding digital ulcers is not uncommonly 
erythematous and/or macerated (including in the absence of 
superadded infection). Patients often report pain (which may be 
severe) associated with digital ulcers. Digital ulcers often have an 
overlying scab (eschar) and if there is a high index of suspicion of 
an underlying digital ulcer, then the lesion should be classified as 
such. Common sites for digital ulcers include the fingertips and over 
the extensor (dorsal) aspects of the hands, and in relation to 
subcutaneous calcinosis. Less often digital ulcers may occur at 
other sites on the hands (e.g. over the lateral aspects of the digits 
and at the base of the nail). 
Healed ulcer A lesion with complete surface epithelisation (otherwise the lesion 
would be classified as a ‘digital ulcer’). 
No ulcer Any lesion which does not fulfil the definitions of either a ‘digital 
ulcer’ or ‘healed ulcer’ including (but not limited) to: digital pitting 
scars, hyperkeratosis, and fissures. 
 
Table 1: Proposed UKSSG working group DU definitions.  
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Figure 1: Example images of the proposed UKSSG DU definitions demonstrating 
different degrees of agreement among raters. A: High agreement (23 ‘DU’). B: High 
agreement (3 ‘no ulcer’, 20 ‘healed ulcer’, 0 ‘DU’). C: Low agreement (10 ‘no ulcer’, 0 
‘healed ulcer’, 13 ‘DU’). D: Low agreement (16 ‘no ulcer’, 0 ‘healed ulcer’, 7 ‘DU’). 
